I don't think there are any serious investors looking at this message board. It's basically some clown spamming about short hedge fund. Stemoron posting under multiple aliases misinformation about trials and lawsuits on both the CUR and STEM message boards. And many posters from the CUR message board returning the favor of the negative SPAM on the CUR message board.
You may have had success with picking stocks in the past on a technical basis but I invest on fundamentals and after years of following these stocks with moderate positions I have invested heavily in some companies in this sector recently and STEM is one of the last places I would park my money. The progress they've made, the results in the trials they've had so far are lacking. There is a reason this stock trades near its all time low with a reverse split adjusted high of $180. You can also compare the market cap to others in the sector to get an idea of what people think of STEM.
And I am a 49 year old engineer.
Soon there will be a discussion about the strange volume at the end of the day. It happens the 3rd Friday of every month. We will be hearing the "somebody knows something"
Looks like J&J just wrote a $35 mil check for Scrap value... and another possible $900 million.
Dr. T is still the lead investigator
Look at CUR. They have patients blogging about the great results. Phase 2 data should be out in a month.
MO. But good luck trying below $3. See you at $7.87
Lots of catalysts coming NSI-189 trial, China Stroke trial data, ALS trial data and an update on Spinal cord trial
Please stop. Nobody knows what the he11 you're talking about.
GRONK got me second place in my fantasy football. He got double or triple the points of all of the other TEs
How can they deny ALS patients who eventually suffocate to death the opportunity.
Nice to be moving up on high volume and no news. I suspect we will get some big news soon.
I don't think a large pharma will agree to partner NSI-189 on limited indications given that it could be used off label. Look at Geron's recent deal with J&J for Imetelstat. J&J has global rights to all cancer indications and Geron gets hefty royalties in return
Not sure why you would think GERN would get royalties from OCAT (ACTC) or Biotime. There was no royalty provision in the transfer of IP to BTX